154 results on '"Geisbert, Thomas W."'
Search Results
2. Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates.
- Author
-
Zeitlin, Larry, Cross, Robert W., Woolsey, Courtney, West, Brandyn R., Borisevich, Viktoriya, Agans, Krystle N., Prasad, Abhishek N., Deer, Daniel J., Stuart, Lauren, McCavitt-Malvido, Maria, Kim, Do H., Pettitt, James, Crowe Jr., James E., Whaley, Kevin J., Veesler, David, Dimitrov, Antony, Abelson, Dafna M., Geisbert, Thomas W., and Broder, Christopher C.
- Subjects
NIPAH virus ,HENDRA virus ,CERCOPITHECUS aethiops ,AUJESZKY'S disease virus ,PRIMATES ,VACCINE approval ,Q fever - Abstract
No licensed vaccines or therapies exist for patients infected with Nipah virus (NiV), although an experimental human monoclonal antibody (mAb) cross-reactive to the NiV and Hendra virus (HeV) G glycoprotein, m102.4, has been tested in a phase 1 trial and has been provided under compassionate use for both HeV and NiV exposures. NiV is a highly pathogenic zoonotic paramyxovirus causing regular outbreaks in humans and animals in South and Southeast Asia. The mortality rate of NiV infection in humans ranges from 40% to more than 90%, making it a substantial public health concern. The NiV G glycoprotein mediates host cell attachment, and the F glycoprotein facilitates membrane fusion and infection. We hypothesized that a mAb against the prefusion conformation of the F glycoprotein may confer better protection than m102.4. To test this, two potent neutralizing mAbs against NiV F protein, hu1F5 and hu12B2, were compared in a hamster model. Hu1F5 provided superior protection to hu12B2 and was selected for comparison with m102.4 for the ability to protect African green monkeys (AGMs) from a stringent NiV challenge. AGMs were exposed intranasally to the Bangladesh strain of NiV and treated 5 days after exposure with either mAb (25 milligrams per kilogram). Whereas only one of six AGMs treated with m102.4 survived until the study end point, all six AGMs treated with hu1F5 were protected. Furthermore, a reduced 10 milligrams per kilogram dose of hu1F5 also provided complete protection against NiV challenge, supporting the upcoming clinical advancement of this mAb for postexposure prophylaxis and therapy. Editor's summary: Nipah virus (NiV) is a zoonotic pathogen that can cause severe disease and death in exposed humans. Unfortunately, no approved vaccines or therapeutics are now available. To advance therapeutic options for NiV, Zeitlin et al. tested the protective efficacy of an antibody targeting the prefusion conformation of the NiV F protein, hu1F5, in hamsters and African green monkeys (AGMs) infected with NiV. Hu1F5 administration at 1 or 5 days after infection conferred protection in hamsters and AGMs, respectively, outperforming a previously developed antibody, m102.4. Together, these results support further clinical development of hu1F5 for NiV infection. —Courtney Malo [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Single-dose VSV-based vaccine protects cynomolgus macaques from disease after Taï Forest virus infection.
- Author
-
Fletcher, Paige, O'Donnell, Kyle L., Doratt, Brianna M., Malherbe, Delphine C., Clancy, Chad S., Rhoderick, Joseph F., Feldmann, Friederike, Hanley, Patrick W., Ksiazek, Thomas G., Geisbert, Thomas W., Messaoudi, Ilhem, and Marzi, Andrea
- Published
- 2023
- Full Text
- View/download PDF
4. High-Avidity Anti-Filovirus IgG Elicited Using Protein Subunit Vaccines Does Not Correlate with Protection.
- Author
-
Williams, Caitlin A., Wong, Teri Ann S., Lieberman, Michael M., Yalley-Ogunro, Jake, Cabus, Mehtap, Nezami, Sara, Paz, Fabian, Andersen, Hanne, Geisbert, Thomas W., and Lehrer, Axel T.
- Subjects
PEPTIDE vaccines ,EBOLA virus disease ,VACCINE effectiveness ,EBOLA virus ,HUMORAL immunity ,SPECIES specificity ,CELLULAR immunity - Abstract
Zaire ebolavirus (EBOV) poses a significant threat to public health due to its high case fatality rate and epidemic potential. This is further complicated by the lack of precise immune correlates of protection and difficulties in conducting in vivo animal studies due to species specificity of Ebola virus disease (EVD) and classification as a biosafety level 4 pathogen. Related ebolaviruses have also contributed to the public health threat; Uganda recently experienced an outbreak of Sudan ebolavirus, which also had a high case fatality rate. Vaccination targeting EBOV has demonstrated significant efficacy; however, the protective cellular and humoral responses at play are still poorly understood. Vaccination for vulnerable populations such as pregnant women, young children, and immunocompromised individuals is still limited. Understanding vaccine correlates of protection (vCOP) is key to developing alternative vaccination strategies for these groups. Components of immunity such as neutralizing antibody and cell-mediated immunity are likely responsible for protective responses; however, existing research fails to fully define their roles in protection. Here we investigated vaccine-elicited antibody avidity as a potential correlate of protection and to further characterize the contribution of antibody avidity in protective and nonprotective vaccine responses. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Perspectives on Advancing Countermeasures for Filovirus Disease: Report From a Multisector Meeting.
- Author
-
Sprecher, Armand, Cross, Robert, Marzi, Andrea, Martins, Karen A, Wolfe, Daniel, Montgomery, Joel M, Spiropoulou, Christina F, Cihlar, Tomas, Ahuka-Mundeke, Steve, Nyhuis, Tara, Teicher, Carrie, Crozier, Ian, Strong, Jim, Kobinger, Gary, Woolsey, Courtney, Geisbert, Thomas W, Feldmann, Heinz, and Muyembe, Jean-Jacques
- Subjects
REPORTING of diseases ,EBOLA virus disease ,VACCINE approval ,DISEASE outbreaks ,CONSORTIA - Abstract
Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are treated with the newly approved therapeutics. Furthermore, these countermeasures are not expected to be effective against disease caused by other filoviruses. A meeting of subject-matter experts was held during the 10
th International Filovirus Symposium to discuss strategies to address these gaps. Several investigational therapeutics, vaccine candidates, and combination strategies were presented. The greatest challenge was identified to be the implementation of well-designed clinical trials of safety and efficacy during filovirus disease outbreaks. Preparing for this will require agreed-upon common protocols for trials intended to bridge multiple outbreaks across all at-risk countries. A multinational research consortium including at-risk countries would be an ideal mechanism to negotiate agreement on protocol design and coordinate preparation. Discussion participants recommended a follow-up meeting be held in Africa to establish such a consortium. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
6. The Mucin-Like Domain of the Ebola Glycoprotein Does Not Impact Virulence or Pathogenicity in Ferrets.
- Author
-
Halfmann, Peter J, Borisevich, Viktoriya, Levine, Corri B, Mire, Chad E, Fenton, Karla A, Geisbert, Thomas W, Kawaoka, Yoshihiro, and Cross, Robert W
- Subjects
FERRET ,EBOLA virus ,VIRAL proteins ,DEATH rate ,ACUTE diseases - Abstract
Background Ebola virus (EBOV) is considered among the most dangerous viruses with case fatality rates approaching 90% depending on the outbreak. While several viral proteins (VPs) including VP24, VP35, and the soluble glycoprotein are understood to contribute to virulence, less is known of the contribution of the highly variable mucin-like domain (MLD) of EBOV. Early studies have defined a potential role in immune evasion of the MLD by providing a glycan shield to critical glycoprotein residues tied to viral entry. Nonetheless, little is known as to what direct role the MLD plays in acute EBOV disease (EVD). Methods We generated an infectious EBOV clone that lacks the MLD and assessed its virulence in ferrets compared with wild-type (WT) virus. Results No differences in growth kinetics were observed in vitro, nor were there any differences in time to death, viremia, or clinical picture in ferrets infected with recombinant EBOV (rEBOV)–WT or rEBOV-Δmucin. Conclusions The EBOV MLD does not play a critical role in acute pathogenesis of EVD in ferrets. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Modelling Marburg Virus Disease in Syrian Golden Hamsters: Contrasted Virulence Between Angola and Ci67 Strains.
- Author
-
Cross, Robert W, Fenton, Karla A, Foster, Stephanie L, Geisbert, Joan B, and Geisbert, Thomas W
- Subjects
MARBURG virus ,GOLDEN hamster ,VIRUS diseases ,HEMORRHAGIC fever ,VACCINE development - Abstract
Background Marburg virus (MARV) has caused numerous sporadic outbreaks of severe hemorrhagic fever in humans. Human case fatality rates of Marburg virus disease (MVD) outbreaks range from 20% to 90%. Viral genotypes of MARV can differ by over 20%, suggesting variable virulence between lineages may accompany this genetic divergence. Comparison of existing animal models of MVD employing different strains of MARV support differences in virulence across MARV genetic lineages; however, there are few systematic comparisons in models that recapitulate human disease available. Methods We compared features of disease pathogenesis in uniformly lethal hamster models of MVD made possible through serial adaptation in rodents. Results No further adaptation from a previously reported guinea pig-adapted (GPA) isolate of MARV-Angola was necessary to achieve uniform lethality in hamsters. Three passages of GPA MARV-Ci67 resulted in uniform lethality, where 4 passages of a GPA Ravn virus was 75% lethal. Hamster-adapted MARV-Ci67 demonstrated delayed time to death, protracted weight loss, lower viral burden, and slower histologic alteration compared to GPA MARV-Angola. Conclusions These data suggest isolate-dependent virulence differences are maintained even after serial adaptation in rodents and may serve to guide choice of variant and model used for development of vaccines or therapeutics for MVD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. A Recombinant Vesicular Stomatitis Virus–Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection.
- Author
-
Woolsey, Courtney, Strampe, Jamie, Fenton, Karla A, Agans, Krystle N, Martinez, Jasmine, Borisevich, Viktoriya, Dobias, Natalie S, Deer, Daniel J, Geisbert, Joan B, Cross, Robert W, Connor, John H, and Geisbert, Thomas W
- Subjects
VESICULAR stomatitis ,EBOLA virus ,VACCINES ,INFECTION ,SURVIVAL rate - Abstract
Background The filovirus Bundibugyo virus (BDBV) causes severe disease with a mortality rate of approximately 20%–51%. The only licensed filovirus vaccine in the United States, Ervebo, consists of a recombinant vesicular stomatitis virus (rVSV) vector that expresses Ebola virus (EBOV) glycoprotein (GP). Ervebo was shown to rapidly protect against fatal Ebola disease in clinical trials; however, the vaccine is only indicated against EBOV. Recent outbreaks of other filoviruses underscore the need for additional vaccine candidates, particularly for BDBV infections. Methods To examine whether the rVSV vaccine candidate rVSVΔG/BDBV-GP could provide therapeutic protection against BDBV, we inoculated seven cynomolgus macaques with 1000 plaque-forming units of BDBV, administering rVSVΔG/BDBV-GP vaccine to 6 of them 20–23 minutes after infection. Results Five of the treated animals survived infection (83%) compared to an expected natural survival rate of 21% in this macaque model. All treated animals showed an early circulating immune response, while the untreated animal did not. Surviving animals showed evidence of both GP-specific IgM and IgG production, while animals that succumbed did not produce significant IgG. Conclusions This small, proof-of-concept study demonstrated early treatment with rVSVΔG/BDBV-GP provides a survival benefit in this nonhuman primate model of BDBV infection, perhaps through earlier initiation of adaptive immunity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus–Infected Rhesus Macaques.
- Author
-
Bushmaker, Trenton, Feldmann, Friederike, Lovaglio, Jamie, Saturday, Greg, Griffin, Amanda J, O'Donnell, Kyle L, Strong, James E, Sprecher, Armand, Kobinger, Gary, Geisbert, Thomas W, Marzi, Andrea, and Feldmann, Heinz
- Subjects
RHESUS monkeys ,VESICULAR stomatitis ,PREVENTIVE medicine ,DISEASE outbreaks ,DISEASE progression - Abstract
Vesicular stomatitis virus–Ebola virus (VSV-EBOV) vaccine has been successfully used in ring vaccination approaches during EBOV disease outbreaks demonstrating its general benefit in short-term prophylactic vaccination, but actual proof of its benefit in true postexposure prophylaxis (PEP) for humans is missing. Animal studies have indicated PEP efficacy when VSV-EBOV was used within hours of lethal EBOV challenge. Here, we used a lower EBOV challenge dose and a combined intravenous and intramuscular VSV-EBOV administration to improve PEP efficacy in the rhesus macaque model. VSV-EBOV treatment 1 hour after EBOV challenge resulted in delayed disease progression but little benefit in outcome. Thus, we could not confirm previous results indicating questionable benefit of VSV-EBOV for EBOV PEP in a nonhuman primate model. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Long-term Prophylaxis Against Aerosolized Marburg Virus in Nonhuman Primates With an Afucosylated Monoclonal Antibody.
- Author
-
Abelson, Dafna, Barajas, Jennifer, Stuart, Lauren, Kim, Do, Marimuthu, Arumugapradeep, Hu, Chris, Yamamoto, Brent, Ailor, Eric, Whaley, Kevin J, Vu, Hong, Agans, Krystle N, Borisevich, Viktoriya, Deer, Daniel J, Dobias, Natalie S, Woolsey, Courtney, Prasad, Abhishek N, Peel, Jennifer E, Lawrence, William S, Cross, Robert W, and Geisbert, Thomas W
- Subjects
MARBURG virus ,MONOCLONAL antibodies ,HEMORRHAGIC fever ,PRIMATES ,BLOOD serum analysis - Abstract
Marburg virus (MARV) causes a hemorrhagic fever disease in human and nonhuman primates with high levels of morbidity and mortality. Concerns about weaponization of aerosolized MARV have spurred the development of nonhuman primate (NHP) models of aerosol exposure. To address the potential threat of aerosol exposure, a monoclonal antibody that binds MARV glycoprotein was tested, MR186
YTE , for its efficacy as a prophylactic. MR186YTE was administered intramuscularly to NHPs at 15 or 5 mg/kg 1 month prior to MARV aerosol challenge. Seventy-five percent (3/4) of the 15 mg/kg dose group and 50% (2/4) of the 5 mg/kg dose group survived. Serum analyses showed that the NHP dosed with 15 mg/kg that succumbed to infection developed an antidrug antibody response and therefore had no detectable MR186YTE at the time of challenge. These results suggest that intramuscular dosing of mAbs may be a clinically useful prophylaxis for MARV aerosol exposure. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
11. Natural History of Nonhuman Primates After Oral Exposure to Ebola Virus Variant Makona.
- Author
-
Prasad, Abhishek N, Agans, Krystle N, Geisbert, Joan B, Borisevich, Viktoriya, Deer, Daniel J, Dobias, Natalie S, Comer, Jason E, Woolsey, Courtney, Fenton, Karla A, Geisbert, Thomas W, and Cross, Robert W
- Subjects
EBOLA virus ,NATURAL history ,EBOLA virus disease ,PRIMATES ,KRA ,LYMPHOPENIA - Abstract
Background The primary route of infection by Ebola virus (EBOV) is through contact of mucosal surfaces. Few studies have explored infection of nonhuman primates (NHPs) via the oral mucosa, which is a probable portal of natural infection in humans. Methods To further characterize the pathogenesis of EBOV infection via the oral exposure route, we challenged cohorts of cynomolgus monkeys with low doses of EBOV variant Makona. Results Infection with 100 or 50 PFU of EBOV Makona via the oral route resulted in 50% and 83% lethality, respectively. Animals that progressed to fatal disease exhibited lymphopenia, marked coagulopathy, high viral loads, and increased levels of serum markers of inflammation and hepatic/renal injury. Survival in these cohorts was associated with milder fluctuations in leukocyte populations, lack of coagulopathy, and reduced or absent serum markers of inflammation and/or hepatic/renal function. Surprisingly, 2 surviving animals from the 100- and 50-PFU cohorts developed transient low-level viremia in the absence of other clinical signs of disease. Conversely, all animals in the 10 PFU cohort remained disease free and survived to the study end point. Conclusions Our observations highlight the susceptibility of NHPs, and by extension, likely humans, to relatively low doses of EBOV via the oral route. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Pathogenesis of Aerosolized Ebola Virus Variant Makona in Nonhuman Primates.
- Author
-
Prasad, Abhishek N, Fenton, Karla A, Agans, Krystle N, Borisevich, Viktoriya, Woolsey, Courtney, Comer, Jason E, Dobias, Natalie S, Peel, Jennifer E, Deer, Daniel J, Geisbert, Joan B, Lawrence, William S, Cross, Robert W, and Geisbert, Thomas W
- Subjects
EBOLA virus ,KRA ,PRIMATES ,PATHOGENESIS ,AEROSOLS ,MASS spectrometers - Abstract
Background Highly pathogenic filoviruses such as Ebola virus (EBOV) hold capacity for delivery by artificial aerosols, and thus potential for intentional misuse. Previous studies have shown that high doses of EBOV delivered by small-particle aerosol cause uniform lethality in nonhuman primates (NHPs), whereas only a few small studies have assessed lower doses in NHPs. Methods To further characterize the pathogenesis of EBOV infection via small-particle aerosol, we challenged cohorts of cynomolgus monkeys with low doses of EBOV variant Makona, which may help define risks associated with small particle aerosol exposures. Results Despite using challenge doses orders of magnitude lower than previous studies, infection via this route was uniformly lethal across all cohorts. Time to death was delayed in a dose-dependent manner between aerosol-challenged cohorts, as well as in comparison to animals challenged via the intramuscular route. Here, we describe the observed clinical and pathological details including serum biomarkers, viral burden, and histopathological changes leading to death. Conclusions Our observations in this model highlight the striking susceptibility of NHPs, and likely humans, via small-particle aerosol exposure to EBOV and emphasize the need for further development of diagnostics and postexposure prophylactics in the event of intentional release via deployment of an aerosol-producing device. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus.
- Author
-
Woolsey, Courtney, Borisevich, Viktoriya, Agans, Krystle N, O'Toole, Rachel, Fenton, Karla A, Harrison, Mack B, Prasad, Abhishek N, Deer, Daniel J, Gerardi, Cheryl, Morrison, Nneka, Cross, Robert W, Eldridge, John H, Matassov, Demetrius, and Geisbert, Thomas W
- Subjects
MARBURG virus ,EBOLA virus ,VESICULAR stomatitis ,ANTIBODY titer ,KRA - Abstract
Background The family Filoviridae consists of several virus members known to cause significant mortality and disease in humans. Among these, Ebola virus (EBOV), Marburg virus (MARV), Sudan virus (SUDV), and Bundibugyo virus (BDBV) are considered the deadliest. The vaccine, Ervebo, was shown to rapidly protect humans against Ebola disease, but is indicated only for EBOV infections with limited cross-protection against other filoviruses. Whether multivalent formulations of similar recombinant vesicular stomatitis virus (rVSV)–based vaccines could likewise confer rapid protection is unclear. Methods Here, we tested the ability of an attenuated, quadrivalent panfilovirus VesiculoVax vaccine (rVSV-Filo) to elicit fast-acting protection against MARV, EBOV, SUDV, and BDBV. Groups of cynomolgus monkeys were vaccinated 7 days before exposure to each of the 4 viral pathogens. All subjects (100%) immunized 1 week earlier survived MARV, SUDV, and BDBV challenge; 80% survived EBOV challenge. Survival correlated with lower viral load, higher glycoprotein-specific immunoglobulin G titers, and the expression of B-cell–, cytotoxic cell–, and antigen presentation–associated transcripts. Conclusions These results demonstrate multivalent VesiculoVax vaccines are suitable for filovirus outbreak management. The highly attenuated nature of the rVSV-Filo vaccine may be preferable to the Ervebo "delta G" platform, which induced adverse events in a subset of recipients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Animal Models for Henipavirus Research.
- Author
-
Pigeaud, Declan D., Geisbert, Thomas W., and Woolsey, Courtney
- Subjects
ANIMAL models in research ,GUINEA pigs ,NIPAH virus ,FERRET ,HENIPAVIRUSES ,PARAMYXOVIRUSES - Abstract
Hendra virus (HeV) and Nipah virus (NiV) are zoonotic paramyxoviruses in the genus Henipavirus (HNV) that emerged nearly thirty years ago. Outbreaks of HeV and NiV have led to severe respiratory disease and encephalitis in humans and animals characterized by a high mortality rate. Despite the grave threat HNVs pose to public health and global biosecurity, no approved medical countermeasures for human use currently exist against HeV or NiV. To develop candidate vaccines and therapeutics and advance the field's understanding of HNV pathogenesis, animal models of HeV and NiV have been instrumental and remain indispensable. Various species, including rodents, ferrets, and nonhuman primates (NHPs), have been employed for HNV investigations. Among these, NHPs have demonstrated the closest resemblance to human HNV disease, although other animal models replicate some key disease features. Here, we provide a comprehensive review of the currently available animal models (mice, hamsters, guinea pigs, ferrets, cats, dogs, nonhuman primates, horses, and swine) to support HNV research. We also discuss the strengths and limitations of each model for conducting pathogenesis and transmission studies on HeV and NiV and for the evaluation of medical countermeasures. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. A Recombinant Chimeric Cedar Virus-Based Surrogate Neutralization Assay Platform for Pathogenic Henipaviruses.
- Author
-
Amaya, Moushimi, Yin, Randy, Yan, Lianying, Borisevich, Viktoriya, Adhikari, Bishwo N., Bennett, Andrew, Malagon, Francisco, Cer, Regina Z., Bishop-Lilly, Kimberly A., Dimitrov, Antony S., Cross, Robert W., Geisbert, Thomas W., and Broder, Christopher C.
- Subjects
HENIPAVIRUSES ,GREEN fluorescent protein ,TYPE I interferons ,REVERSE genetics ,ANIMAL diseases ,MONOCLONAL antibodies ,CHIMERIC proteins - Abstract
The henipaviruses, Nipah virus (NiV), and Hendra virus (HeV) can cause fatal diseases in humans and animals, whereas Cedar virus is a nonpathogenic henipavirus. Here, using a recombinant Cedar virus (rCedV) reverse genetics platform, the fusion (F) and attachment (G) glycoprotein genes of rCedV were replaced with those of NiV-Bangladesh (NiV-B) or HeV, generating replication-competent chimeric viruses (rCedV-NiV-B and rCedV-HeV), both with and without green fluorescent protein (GFP) or luciferase protein genes. The rCedV chimeras induced a Type I interferon response and utilized only ephrin-B2 and ephrin-B3 as entry receptors compared to rCedV. The neutralizing potencies of well-characterized cross-reactive NiV/HeV F and G specific monoclonal antibodies against rCedV-NiV-B-GFP and rCedV-HeV-GFP highly correlated with measurements obtained using authentic NiV-B and HeV when tested in parallel by plaque reduction neutralization tests (PRNT). A rapid, high-throughput, and quantitative fluorescence reduction neutralization test (FRNT) using the GFP-encoding chimeras was established, and monoclonal antibody neutralization data derived by FRNT highly correlated with data derived by PRNT. The FRNT assay could also measure serum neutralization titers from henipavirus G glycoprotein immunized animals. These rCedV chimeras are an authentic henipavirus-based surrogate neutralization assay that is rapid, cost-effective, and can be utilized outside high containment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Natural history of nonhuman primates after conjunctival exposure to Ebola virus.
- Author
-
Cross, Robert W., Prasad, Abhishek N., Woolsey, Courtney B., Agans, Krystle N., Borisevich, Viktoriya, Dobias, Natalie S., Comer, Jason E., Deer, Daniel J., Geisbert, Joan B., Rasmussen, Angela L., Lipkin, Walter Ian, Fenton, Karla A., and Geisbert, Thomas W.
- Subjects
EBOLA virus ,DELAYED onset of disease ,NATURAL history ,PRIMATES ,EXPOSURE dose - Abstract
Transmission of Ebola virus (EBOV) primarily occurs via contact exposure of mucosal surfaces with infected body fluids. Historically, nonhuman primate (NHP) challenge studies have employed intramuscular (i.m.) or small particle aerosol exposure, which are largely lethal routes of infection, but mimic worst-case scenarios such as a needlestick or intentional release, respectively. When exposed by more likely routes of natural infection, limited NHP studies have shown delayed onset of disease and reduced mortality. Here, we performed a series of systematic natural history studies in cynomolgus macaques with a range of conjunctival exposure doses. Challenge with 10,000 plaque forming units (PFU) of EBOV was uniformly lethal, whereas 5/6 subjects survived lower dose challenges (100 or 500 PFU). Conjunctival challenge resulted in a protracted time-to death compared to i.m. Asymptomatic infection was observed in survivors with limited detection of EBOV replication. Inconsistent seropositivity in survivors may suggest physical or natural immunological barriers are sufficient to prevent widespread viral dissemination. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Marburg and Ebola Virus Infections Elicit a Complex, Muted Inflammatory State in Bats.
- Author
-
Jayaprakash, Anitha D., Ronk, Adam J., Prasad, Abhishek N., Covington, Michael F., Stein, Kathryn R., Schwarz, Toni M., Hekmaty, Saboor, Fenton, Karla A., Geisbert, Thomas W., Basler, Christopher F., Bukreyev, Alexander, and Sachidanandam, Ravi
- Subjects
EBOLA virus disease ,MARBURG virus ,INFLAMMATION ,BAT diseases ,EBOLA virus - Abstract
The Marburg and Ebola filoviruses cause a severe, often fatal, disease in humans and nonhuman primates but have only subclinical effects in bats, including Egyptian rousettes, which are a natural reservoir of Marburg virus. A fundamental question is why these viruses are highly pathogenic in humans but fail to cause disease in bats. To address this question, we infected one cohort of Egyptian rousette bats with Marburg virus and another cohort with Ebola virus and harvested multiple tissues for mRNA expression analysis. While virus transcripts were found primarily in the liver, principal component analysis (PCA) revealed coordinated changes across multiple tissues. Gene signatures in kidney and liver pointed at induction of vasodilation, reduction in coagulation, and changes in the regulation of iron metabolism. Signatures of immune response detected in spleen and liver indicated a robust anti-inflammatory state signified by macrophages in the M2 state and an active T cell response. The evolutionary divergence between bats and humans of many responsive genes might provide a framework for understanding the differing outcomes upon infection by filoviruses. In this study, we outline multiple interconnected pathways that respond to infection by MARV and EBOV, providing insights into the complexity of the mechanisms that enable bats to resist the disease caused by filoviral infections. The results have the potential to aid in the development of new strategies to effectively mitigate and treat the disease caused by these viruses in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates.
- Author
-
Hunegnaw, Ruth, Honko, Anna N., Wang, Lingshu, Carr, Derick, Murray, Tamar, Shi, Wei, Nguyen, Lam, Storm, Nadia, Dulan, Caitlyn N. M., Foulds, Kathryn E., Agans, Krystle N., Cross, Robert W., Geisbert, Joan B., Cheng, Cheng, Ploquin, Aurélie, Stanley, Daphne A., Geisbert, Thomas W., Nabel, Gary J., and Sullivan, Nancy J.
- Subjects
EBOLA virus ,MARBURG virus ,HEMORRHAGIC fever ,VACCINE effectiveness ,PRIMATES ,PRIMATE diseases - Abstract
Marburg virus (MARV) causes a severe hemorrhagic fever disease in primates with mortality rates in humans of up to 90%. MARV has been identified as a category A bioterrorism agent by the Centers for Disease Control and Prevention (CDC) and priority pathogen A by the National Institute of Allergy and Infectious Diseases (NIAID), needing urgent research and development of countermeasures because of the high public health risk it poses. The recent cases of MARV in West Africa underscore the substantial outbreak potential of this virus. The potential for cross-border spread, as had occurred during the 2014–2016 Ebola virus outbreak, illustrates the critical need for MARV vaccines. To support regulatory approval of the chimpanzee adenovirus 3 (ChAd3)–MARV vaccine that has completed phase 1 trials, we showed that the nonreplicating ChAd3 vector, which has a demonstrated safety profile in humans, protected against a uniformly lethal challenge with MARV/Ang. Protective immunity was achieved within 7 days of vaccination and was maintained through 1 year after vaccination. Antigen-specific antibodies were an immune correlate of protection in the acute challenge model, and their concentration was predictive of protection. These results demonstrate that a single-shot ChAd3-MARV vaccine generated a protective immune response that was both rapid and durable with an immune correlate of protection that will support advanced clinical development. Fighting filoviruses: Fighting filovirusesMarburg Virus (MARV) outbreaks remain a major global health concern, and an effective vaccine is urgently needed. Here, Hunegnaw et al. report that a single-shot chimpanzee adenovirus-vectored vaccine expressing the MARV glycoprotein, ChAd3-MARV, confers protection in non-human primates. Animals were protected as soon as one week after vaccination and protection lasted up to a year after vaccination, with antigen-specific antibodies serving as a predictor of protection. Together, these results support clinical use of ChAd3-MARV. -CM [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Lessons from the pandemic: Responding to emerging zoonotic viral diseases—a Keystone Symposia report.
- Author
-
Cable, Jennifer, Fauci, Anthony, Dowling, William E., Günther, Stephan, Bente, Dennis A., Yadav, Pragya Dhruv, Madoff, Lawrence C., Wang, Lin‐Fa, Arora, Rahul K., Van Kerkhove, Maria, Chu, May C., Jaenisch, Thomas, Epstein, Jonathan H., Frost, Simon David William, Bausch, Daniel G., Hensley, Lisa E., Bergeron, Éric, Sitaras, Ioannis, Gunn, Michael D., and Geisbert, Thomas W.
- Subjects
VIRUS diseases ,ZOONOSES ,PANDEMICS ,COVID-19 pandemic ,NIPAH virus ,PLANT viruses - Abstract
The COVID‐19 pandemic caught the world largely unprepared, including scientific and policy communities. On April 10–13, 2022, researchers across academia, industry, government, and nonprofit organizations met at the Keystone symposium "Lessons from the Pandemic: Responding to Emerging Zoonotic Viral Diseases" to discuss the successes and challenges of the COVID‐19 pandemic and what lessons can be applied moving forward. Speakers focused on experiences not only from the COVID‐19 pandemic but also from outbreaks of other pathogens, including the Ebola virus, Lassa virus, and Nipah virus. A general consensus was that investments made during the COVID‐19 pandemic in infrastructure, collaborations, laboratory and manufacturing capacity, diagnostics, clinical trial networks, and regulatory enhancements—notably, in low‐to‐middle income countries—must be maintained and strengthened to enable quick, concerted responses to future threats, especially to zoonotic pathogens. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Natural history of Sudan ebolavirus infection in rhesus and cynomolgus macaques.
- Author
-
Woolsey, Courtney, Fears, Alyssa C., Borisevich, Viktoriya, Agans, Krystle N., Dobias, Natalie S., Prasad, Abhishek N., Deer, Daniel J., Geisbert, Joan B., Fenton, Karla A., Geisbert, Thomas W., and Cross, Robert W.
- Published
- 2022
- Full Text
- View/download PDF
21. An introduction to the Marburg virus vaccine consortium, MARVAC.
- Author
-
Cross, Robert W., Longini, Ira M., Becker, Stephan, Bok, Karin, Boucher, David, Carroll, Miles W., Díaz, Janet V., Dowling, William E., Draghia-Akli, Ruxandra, Duworko, James T., Dye, John M., Egan, Michael A., Fast, Patricia, Finan, Amy, Finch, Courtney, Fleming, Thomas R., Fusco, Joan, Geisbert, Thomas W., Griffiths, Anthony, and Günther, Stephan
- Subjects
MARBURG virus ,VIRAL vaccines ,CONSORTIA ,VACCINE development ,COMMUNICABLE diseases - Abstract
The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the MARV vaccine "MARVAC" consortium representing leaders in the field of vaccine research and development aiming to facilitate a rapid response to this infectious disease threat. Here, we discuss current progress, challenges, and future directions for MARV vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical Trials.
- Author
-
Cooper, Christopher L., Morrow, Gavin, Yuan, Maoli, Coleman, John W., Hou, Fuxiang, Reiserova, Lucia, Li, Shui L., Wagner, Denise, Carpov, Alexei, Wallace-Selman, Olivia, Valentin, Kristie, Choi, Yesle, Wilson, Aaron, Kilianski, Andrew, Sayeed, Eddy, Agans, Krystle N., Borisevich, Viktoriya, Cross, Robert W., Geisbert, Thomas W., and Feinberg, Mark B.
- Subjects
MARBURG virus ,VESICULAR stomatitis ,VIRUS diseases ,VIRAL vaccines ,HIV seroconversion ,VACCINATION - Abstract
Vaccines are needed to disrupt or prevent continued outbreaks of filoviruses in humans across Western and Central Africa, including outbreaks of Marburg virus (MARV). As part of a filovirus vaccine product development plan, it is important to investigate dose response early in preclinical development to identify the dose range that may be optimal for safety, immunogenicity, and efficacy, and perhaps demonstrate that using lower doses is feasible, which will improve product access. To determine the efficacious dose range for a manufacturing-ready live recombinant vesicular stomatitis virus vaccine vector (rVSV∆G-MARV-GP) encoding the MARV glycoprotein (GP), a dose-range study was conducted in cynomolgus macaques. Results showed that a single intramuscular injection with as little as 200 plaque-forming units (PFUs) was 100% efficacious against lethality and prevented development of viremia and clinical pathologies associated with MARV Angola infection. Across the vaccine doses tested, there was nearly a 2000-fold range of anti-MARV glycoprotein (GP) serum IgG titers with seroconversion detectable even at the lowest doses. Virus-neutralizing serum antibodies also were detected in animals vaccinated with the higher vaccine doses indicating that vaccination induced functional antibodies, but that the assay was a less sensitive indicator of seroconversion. Collectively, the data indicates that a relatively wide range of anti-GP serum IgG titers are observed in animals that are protected from disease implying that seroconversion is positively associated with efficacy, but that more extensive immunologic analyses on samples collected from our study as well as future preclinical studies will be valuable in identifying additional immune responses correlated with protection that can serve as markers to monitor in human trials needed to generate data that can support vaccine licensure in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus Immunotherapeutic.
- Author
-
Kuang, Erin, Cross, Robert W., McCavitt-Malvido, Maria, Abelson, Dafna M., Borisevich, Viktoriya, Stuart, Lauren, Agans, Krystle N., Mlakar, Neil, Marimuthu, Arumugapradeep, Deer, Daniel J., Shestowsky, William S., Kim, Do, Geisbert, Joan B., Zeitlin, Larry, Moyer, Crystal L., Roy, Chad J., Geisbert, Thomas W., and Bornholdt, Zachary A.
- Subjects
INTRAMUSCULAR injections ,EBOLA virus ,MONOCLONAL antibodies ,COCKTAILS - Abstract
Intravenous (IV) administration of antiviral monoclonal antibodies (mAbs) can be challenging, particularly during an ongoing epidemic, due to the considerable resources required for performing infusions. An ebolavirus therapeutic administered via intramuscular (IM) injection would reduce the burdens associated with IV infusion and allow rapid treatment of exposed individuals during an outbreak. Here, we demonstrate how MBP134, a cocktail of two pan-ebolavirus mAbs, reverses the course of Sudan ebolavirus disease (Gulu variant) with a single IV or IM dose in non-human primates (NHPs) as late as five days post-exposure. We also investigate the utility of adding half-life extension mutations to the MBP134 mAbs, ultimately creating a half-life extended cocktail designated MBP431. When delivered as a post-exposure prophylactic or therapeutic, a single IM dose of MBP431 offered complete or significant protection in NHPs challenged with Zaire ebolavirus. In conjunction with previous studies, these results support the use of MBP431 as a rapidly deployable IM medical countermeasure against every known species of ebolavirus. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge.
- Author
-
Woolsey, Courtney, Cross, Robert W., Agans, Krystle N., Borisevich, Viktoriya, Deer, Daniel J., Geisbert, Joan B., Gerardi, Cheryl, Latham, Theresa E., Fenton, Karla A., Egan, Michael A., Eldridge, John H., Geisbert, Thomas W., and Matassov, Demetrius
- Subjects
MARBURG virus ,EBOLA virus disease ,JOINT pain ,VESICULAR stomatitis ,VIRUS diseases - Abstract
Background: Marburg virus (MARV), an Ebola-like virus, remains an eminent threat to public health as demonstrated by its high associated mortality rate (23–90%) and recent emergence in West Africa for the first time. Although a recombinant vesicular stomatitis virus (rVSV)-based vaccine (Ervebo) is licensed for Ebola virus disease (EVD), no approved countermeasures exist against MARV. Results from clinical trials indicate Ervebo prevents EVD in 97.5–100% of vaccinees 10 days onwards post-immunization. Methodology/Findings: Given the rapid immunogenicity of the Ervebo platform against EVD, we tested whether a similar, but highly attenuated, rVSV-based Vesiculovax vector expressing the glycoprotein (GP) of MARV (rVSV-N4CT1-MARV-GP) could provide swift protection against Marburg virus disease (MVD). Here, groups of cynomolgus monkeys were vaccinated 7, 5, or 3 days before exposure to a lethal dose of MARV (Angola variant). All subjects (100%) immunized one week prior to challenge survived; 80% and 20% of subjects survived when vaccinated 5- and 3-days pre-exposure, respectively. Lethality was associated with higher viral load and sustained innate immunity transcriptional signatures, whereas survival correlated with development of MARV GP-specific antibodies and early expression of predicted NK cell-, B-cell-, and cytotoxic T-cell-type quantities. Conclusions/Significance: These results emphasize the utility of Vesiculovax vaccines for MVD outbreak management. The highly attenuated nature of rVSV-N4CT1 vaccines, which are clinically safe in humans, may be preferable to vaccines based on the same platform as Ervebo (rVSV "delta G" platform), which in some trial participants induced vaccine-related adverse events in association with viral replication including arthralgia/arthritis, dermatitis, and cutaneous vasculitis. Author summary: Marburg virus (MARV) is one of the deadliest viruses known to man. One of the most effective vaccines against this pathogen uses a recombinant vesicular stomatitis virus (rVSV) platform to express MARV glycoprotein (GP) immunogen. As rVSV-based vaccines may be used as medical interventions to mitigate or prevent outbreaks of MARV, defining the time window needed to elicit protection is vital. Here, a rVSV vector expressing MARV glycoprotein (rVSV-N4CT1-MARV-GP) fully protected nonhuman primates from lethality and disease when given as soon as 1 week prior to exposure. At 5- and 3-days pre-exposure, partial protection (80% and 20% survival, respectively) was achieved. Vaccination with rVSV-N4CT1-MARV-GP appears to "jump-start" the immune system to allow sufficient time for MARV-specific adaptive responses to form. This fast-acting vaccine is based on a similar platform as Ervebo, the only FDA- and EMA-approved vaccine for preventing Ebola virus infection. The rVSV-N4CT1-MARV-GP vaccine features additional attenuations in the rVSV backbone that may contribute to a more acceptable safety profile in vaccinees, as Ervebo in some recipients induced vaccine-related adverse events including rashes and joint pain. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease.
- Author
-
Foster, Stephanie L., Woolsey, Courtney, Borisevich, Viktoriya, Agans, Krystle N., Prasad, Abhishek N., Deer, Daniel J., Geisbert, Joan B., Dobias, Natalie S., Fenton, Karla A., Cross, Robert W., and Geisbert, Thomas W.
- Subjects
NIPAH virus ,VIRUS diseases ,KILLER cells ,CYTOTOXIC T cells ,CERCOPITHECUS aethiops - Abstract
Nipah virus (NiV) is an emerging highly lethal zoonotic disease that, like SARS-CoV-2, can be transmitted via respiratory droplets. Single-injection vaccines that rapidly control NiV outbreaks are needed. To assess the ability of a vaccine to induce fast-acting protection, we immunized African green monkeys with a recombinant vesicular stomatitis virus (VSV) expressing the Bangladesh strain glycoprotein (NiV
B G) of NiV (rVSV-ΔGNiVB G). Monkeys were challenged 3 or 7 d later with a lethal dose of NiVB . All monkeys vaccinated with rVSV-ΔG-NiVB G 7 d prior to NiVB exposure were protected from lethal disease, while 67% of animals vaccinated 3 d before NiVB challenge survived. Vaccine protection correlated with natural killer cell and cytotoxic T cell transcriptional signatures, whereas lethality was linked to sustained interferon signaling. NiV G-specific antibodies in vaccinated survivors corroborated additional transcriptomic findings, supporting activation of humoral immunity. This study demonstrates that rVSV-based vaccines may have utility in rapidly protecting humans against NiV infection. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
26. Current state of Ebola virus vaccines: A snapshot.
- Author
-
Woolsey, Courtney and Geisbert, Thomas W.
- Subjects
VIRAL vaccines ,EBOLA virus ,MEDICAL personnel ,EBOLA virus disease ,VACCINE effectiveness ,HIV-positive children ,ADENOVIRUS diseases - Abstract
Other EBOV vaccine candidates where Phase I trial data have been published include a 2-dose DNA vaccine targeting EBOV [[28]], a bivalent DNA plasmid vaccine targeting EBOV and MARV [[29]], and a 2-dose monovalent nanoparticle recombinant EBOV GP vaccine [[31]]. Ervebo (rVSV-EBOV; V920) Ervebo is a live-attenuated, replication-competent, single-dose vaccine originally developed and shown to completely protect nonhuman primates (NHPs) by scientists at the Public Health Agency of Canada and the US Army [[10]]. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response. While substantial progress has been made in the development of EBOV vaccines, multiple questions remain unanswered including the following: (1) what is the durability and the immediacy of immune responses generated by different vaccines; (2) what are the specific correlates and thresholds of protection; (3) do any interactions or interferences exist between vaccines and potential therapeutics; (4) what is the safety of these vaccines in special populations, particularly pregnant women and the immunocompromised; and (5) can vaccines be formulated to be stable for long-term storage at 2 to 8°C, which would be useful in endemic areas [[8]]?. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
27. Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses.
- Author
-
Lehrer, Axel T., Chuang, Eleanore, Namekar, Madhuri, Williams, Caitlin A., Wong, Teri Ann S., Lieberman, Michael M., Granados, Alex, Misamore, John, Yalley-Ogunro, Jake, Andersen, Hanne, Geisbert, Joan B., Agans, Krystle N., Cross, Robert W., and Geisbert, Thomas W.
- Subjects
MARBURG virus ,RECOMBINANT proteins ,EBOLA virus disease ,MACAQUES ,VIRUS diseases - Abstract
Ebola (EBOV), Marburg (MARV) and Sudan (SUDV) viruses are the three filoviruses which have caused the most fatalities in humans. Transmission from animals into the human population typically causes outbreaks of limited scale in endemic regions. In contrast, the 2013-16 outbreak in several West African countries claimed more than 11,000 lives revealing the true epidemic potential of filoviruses. This is further emphasized by the difficulty seen with controlling the 2018-2020 outbreak of EBOV in the Democratic Republic of Congo (DRC), despite the availability of two emergency use-approved vaccines and several experimental therapeutics targeting EBOV. Moreover, there are currently no vaccine options to protect against the other epidemic filoviruses. Protection of a monovalent EBOV vaccine against other filoviruses has never been demonstrated in primate challenge studies substantiating a significant void in capability should a MARV or SUDV outbreak of similar magnitude occur. Herein we show progress on developing vaccines based on recombinant filovirus glycoproteins (GP) from EBOV, MARV and SUDV produced using the Drosophila S2 platform. The highly purified recombinant subunit vaccines formulated with CoVaccine HT™ adjuvant have not caused any safety concerns (no adverse reactions or clinical chemistry abnormalities) in preclinical testing. Candidate formulations elicit potent immune responses in mice, guinea pigs and non-human primates (NHPs) and consistently produce high antigen-specific IgG titers. Three doses of an EBOV candidate vaccine elicit full protection against lethal EBOV infection in the cynomolgus challenge model while one of four animals infected after only two doses showed delayed onset of Ebola Virus Disease (EVD) and eventually succumbed to infection while the other three animals survived challenge. The monovalent MARV or SUDV vaccine candidates completely protected cynomolgus macaques from infection with lethal doses of MARV or SUDV. It was further demonstrated that combinations of MARV or SUDV with the EBOV vaccine can be formulated yielding bivalent vaccines retaining full efficacy. The recombinant subunit vaccine platform should therefore allow the development of a safe and efficacious multivalent vaccine candidate for protection against Ebola, Marburg and Sudan Virus Disease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
28. Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge.
- Author
-
Sorvillo, Teresa E., Cross, Robert W., Johnson, Dylan M., Dobias, Natalie S., Fenton, Karla A., Mire, Chad E., and Geisbert, Thomas W.
- Subjects
GUINEA pigs ,VESICULAR stomatitis ,BIOSECURITY ,IMMUNOGLOBULIN G ,ANTIBODY formation ,VACCINE effectiveness - Abstract
Junin virus (JUNV) is a pathogen of biodefense importance due to its potential for aerosol transmission and mortality rates reaching 30%. Currently, there are no JUNV vaccines licensed by the United States Food and Drug Administration (FDA) for at-risk individuals. A vaccine based on recombinant vesicular stomatitis virus (rVSV) has been effectively used to prevent Ebola virus disease in humans. Here, we evaluated the protective efficacy of a rVSV expressing the JUNV glycoprotein (rVSVΔG-JUNVGP) in a guinea pig model of lethal JUNV disease. Two groups of guinea pigs, one prime and one prime-boost, were vaccinated with rVSVΔG-JUNVGP; six control animals remained unvaccinated. Survival for prime and prime-boost vaccinated animals was 100% while the challenge virus was uniformly lethal in all control animals. Animals in both vaccine groups developed robust, high avidity IgG antibody titers post-vaccination as well as detectable neutralizing antibodies while control animals failed to develop detectable antibody responses. This study demonstrates for the first time that rVSV expressing the JUNV GP fully protects guinea pigs from lethal JUNV challenge with a single injection vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. Ebola vaccine–induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects.
- Author
-
Meyer, Michelle, Gunn, Bronwyn M., Malherbe, Delphine C., Gangavarapu, Karthik, Yoshida, Asuka, Pietzsch, Colette, Kuzmina, Natalia A., Saphire, Erica Ollmann, Collins, Peter L., Crowe, James E., Zhu, James J., Suchard, Marc A., Brining, Douglas L., Mire, Chad E., Cross, Robert W., Geisbert, Joan B., Samal, Siba K., Andersen, Kristian G., Alter, Galit, and Geisbert, Thomas W.
- Subjects
ANTIBODY specificity ,IMMUNOGLOBULINS ,SURVIVAL rate ,EBOLA virus ,ANTIBODY formation ,PRIMATES - Abstract
Correlates of protection: Vaccines against Ebola virus (EBOV) are difficult to test in humans due to the sporadic nature of EBOV outbreaks, so understanding correlates of protection in preclinical models is necessary. To this end, Meyer et al. tested five candidate mucosal EBOV vaccines in cynomolgus macaques and showed that, despite sharing the EBOV glycoprotein as an antigen, they varied in their ability to protect animals from the EBOV challenge. The authors interrogated correlates of protection and found that functional qualities of the antibody response, such as Fc-mediated effects, were associated with protection. In contrast, neutralizing antibody titers did not correlate with survival. Thus, looking beyond the presence of neutralizing antibodies may be necessary to understand the protective effect of EBOV vaccines. Although substantial progress has been made with Ebola virus (EBOV) vaccine measures, the immune correlates of vaccine-mediated protection remain uncertain. Here, five mucosal vaccine vectors based on human and avian paramyxoviruses provided nonhuman primates with varying degrees of protection, despite expressing the same EBOV glycoprotein (GP) immunogen. Each vaccine produced antibody responses that differed in Fc-mediated functions and isotype composition, as well as in magnitude and coverage toward GP and its conformational and linear epitopes. Differences in the degree of protection and comprehensive characterization of the response afforded the opportunity to identify which features and functions were elevated in survivors and could therefore serve as vaccine correlates of protection. Pairwise network correlation analysis of 139 immune- and vaccine-related parameters was performed to demonstrate relationships with survival. Total GP-specific antibodies, as measured by biolayer interferometry, but not neutralizing IgG or IgA titers, correlated with survival. Fc-mediated functions and the amount of receptor binding domain antibodies were associated with improved survival outcomes, alluding to the protective mechanisms of these vaccines. Therefore, functional qualities of the antibody response, particularly Fc-mediated effects and GP specificity, rather than simply magnitude of the response, appear central to vaccine-induced protection against EBOV. The heterogeneity of the response profile between the vaccines indicates that each vaccine likely exhibits its own protective signature and the requirements for an efficacious EBOV vaccine are complex. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR.
- Author
-
Fontes, Cassio M., Lipes, Barbara D., Liu, Jason, Agans, Krystle N., Yan, Aiwei, Shi, Patricia, Cruz, Daniela F., Kelly, Garrett, Luginbuhl, Kelli M., Joh, Daniel Y., Foster, Stephanie L., Heggestad, Jacob, Hucknall, Angus, Mikkelsen, Maiken H., Pieper, Carl F., Horstmeyer, Roarke W., Geisbert, Thomas W., Gunn, Michael D., and Chilkoti, Ashutosh
- Subjects
IMMUNOASSAY ,EBOLA virus ,DISEASE outbreaks ,POLYMERASE chain reaction ,HEMORRHAGIC fever ,MEDICAL care - Abstract
Detecting disease with a decoy: Low-cost, rapid diagnostic tests that perform as well as PCR and can be used at the point of need can help contain outbreaks of infectious diseases. Fontes et al. developed an immunoassay to detect Ebola virus secreted glycoprotein (sGP), a decoy antigen present in infected blood. The assay detected sGP-spiked human and nonhuman primate serum samples and human blood samples spiked with Sudan ebolavirus and Bundibugyo ebolavirus. The immunoassay had a lower limit of detection than other lateral flow rapid diagnostic tests for Ebola virus and detected sGP earlier than PCR using samples from infected nonhuman primates. Results support the use of the immunoassay for rapid detection of Ebola virus. Ebola virus (EBOV) hemorrhagic fever outbreaks have been challenging to deter due to the lack of health care infrastructure in disease-endemic countries and a corresponding inability to diagnose and contain the disease at an early stage. EBOV vaccines and therapies have improved disease outcomes, but the advent of an affordable, easily accessed, mass-produced rapid diagnostic test (RDT) that matches the performance of more resource-intensive polymerase chain reaction (PCR) assays would be invaluable in containing future outbreaks. Here, we developed and demonstrated the performance of a new ultrasensitive point-of-care immunoassay, the EBOV D4 assay, which targets the secreted glycoprotein of EBOV. The EBOV D4 assay is 1000-fold more sensitive than the U.S. Food and Drug Administration–approved RDTs and detected EBOV infection earlier than PCR in a standard nonhuman primate model. The EBOV D4 assay is suitable for low-resource settings and may facilitate earlier detection, containment, and treatment during outbreaks of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Combination therapy protects macaques against advanced Marburg virus disease.
- Author
-
Cross, Robert W., Bornholdt, Zachary A., Prasad, Abhishek N., Borisevich, Viktoriya, Agans, Krystle N., Deer, Daniel J., Abelson, Dafna M., Kim, Do H., Shestowsky, William S., Campbell, Lioudmila A., Bunyan, Elaine, Geisbert, Joan B., Fenton, Karla A., Zeitlin, Larry, Porter, Danielle P., and Geisbert, Thomas W.
- Subjects
VIRUS diseases ,MARBURG virus ,RHESUS monkeys ,REMDESIVIR ,EBOLA virus ,MACAQUES ,MONOCLONAL antibodies - Abstract
Monoclonal antibodies (mAbs) and remdesivir, a small-molecule antiviral, are promising monotherapies for many viruses, including members of the genera Marburgvirus and Ebolavirus (family Filoviridae), and more recently, SARS-CoV-2. One of the major challenges of acute viral infections is the treatment of advanced disease. Thus, extending the window of therapeutic intervention is critical. Here, we explore the benefit of combination therapy with a mAb and remdesivir in a non-human primate model of Marburg virus (MARV) disease. While rhesus monkeys are protected against lethal infection when treatment with either a human mAb (MR186-YTE; 100%), or remdesivir (80%), is initiated 5 days post-inoculation (dpi) with MARV, no animals survive when either treatment is initiated alone beginning 6 dpi. However, by combining MR186-YTE with remdesivir beginning 6 dpi, significant protection (80%) is achieved, thereby extending the therapeutic window. These results suggest value in exploring combination therapy in patients presenting with advanced filovirus disease. Extending the therapeutic window for acute viral infections could save lives. Here, the authors show that combination treatment with a human monoclonal antibody and remdesivir initiated at 6 days post infection with Marburg virus provides 80% protection in non-human primates. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody.
- Author
-
Zeitlin, Larry, Cross, Robert W., Geisbert, Joan B., Borisevich, Viktoriya, Agans, Krystle N., Prasad, Abhishek N., Enterlein, Sven, Aman, M. Javad, Bornholdt, Zachary A., Brennan, Miles B., Campbell, Lioudmila, Do Kim, Mlakar, Neil, Moyer, Crystal L., Pauly, Michael H., Shestowsky, William, Whaley, Kevin J., Fenton, Karla A., and Geisbert, Thomas W.
- Subjects
HEMORRHAGIC fever ,MONOCLONAL antibodies ,CONVALESCENT plasma ,COVID-19 pandemic ,KRA - Abstract
The COVID-19 pandemic has reemphasized the need to identify safe and scalable therapeutics to slow or reverse symptoms of disease caused by newly emerging and reemerging viral pathogens. Recent clinical successes of monoclonal antibodies (mAbs) in therapy for viral infections demonstrate that mAbs offer a solution for these emerging biothreats. We have explored this with respect to Junin virus (JUNV), an arenavirus classified as a category A high-priority agent and the causative agent of Argentine hemorrhagic fever (AHF). There are currently no Food and Drug Administration-approved drugs available for preventing or treating AHF, although immune plasma from convalescent patients is used routinely to treat active infections. However, immune plasma is severely limited in quantity, highly variable in quality, and poses significant safety risks including the transmission of transfusion-borne diseases. mAbs offer a highly specific and consistently potent alternative to immune plasma that can be manufactured at large scale. We previously described a chimeric mAb, cJ199, that provided protection in a guinea pig model of AHF. To adapt this mAb to a format more suitable for clinical use, we humanized the mAb (hu199) and evaluated it in a cynomolgus monkey model of AHF with two JUNV isolates, Romero and Espindola. While untreated control animals experienced 100% lethality, all animals treated with hu199 at 6 d postinoculation (dpi) survived, and 50% of animals treated at 8 dpi survived. mAbs like hu199 may offer a safer, scalable, and more reproducible alternative to immune plasma for rare viral diseases that have epidemic potential. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
33. A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus.
- Author
-
Geisbert, Thomas W., Bobb, Kathryn, Borisevich, Viktoriya, Geisbert, Joan B., Agans, Krystle N., Cross, Robert W., Prasad, Abhishek N., Fenton, Karla A., Yu, Hao, Fouts, Timothy R., Broder, Christopher C., and Dimitrov, Antony S.
- Subjects
NIPAH virus ,VIRAL vaccines ,GLYCOPROTEINS ,CLINICAL trials ,IMMUNOGENETICS - Abstract
Nipah and Hendra viruses are highly pathogenic bat-borne paramyxoviruses recently included in the WHO Blueprint priority diseases list. A fully registered horse anti-Hendra virus subunit vaccine has been in use in Australia since 2012. Based on the same immunogen, the Hendra virus attachment glycoprotein ectodomain, a subunit vaccine formulation for use in people is now in a Phase I clinical trial. We report that a single dose vaccination regimen of this human vaccine formulation protects against otherwise lethal challenges of either Hendra or Nipah virus in a nonhuman primate model. The protection against the Nipah Bangladesh strain begins as soon as 7 days post immunization with low dose of 0.1 mg protein subunit. Our data suggest this human vaccine could be utilized as efficient emergency vaccine to disrupt potential spreading of Nipah disease in an outbreak setting. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
34. Endotheliopathy and Platelet Dysfunction as Hallmarks of Fatal Lassa Fever.
- Author
-
Horton, Lucy E., Cross, Robert W., Hartnett, Jessica N., Engel, Emily J., Sakabe, Saori, Goba, Augustine, Momoh, Mambu, Sandi, John Demby, Geisbert, Thomas W., Garry, Robert F., Schieffelin, John S., Grant, Donald S., and Sullivan, Brian M.
- Abstract
Lassa fever (LF) causes multisystem disease and has a fatality rate <70%. Severe cases exhibit abnormal coagulation, endothelial barrier disruption, and dysfunctional platelet aggregation but the underlying mechanisms remain poorly understood. In Sierra Leone during 2015-2018, we assessed LF patients' day-of-admission plasma samples for levels of proteins necessary for coagulation, fibrinolysis, and platelet function. P-selectin, soluble endothelial protein C receptor, soluble thrombomodulin, plasminogen activator inhibitor 1, ADAMTS-13, von Willebrand factor, tissue factor, soluble intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 were more elevated in LF patients than in controls. Endothelial protein C receptor, thrombomodulin, intercellular adhesion molecule 1, plasminogen activator inhibitor 1, D-dimer, and hepatocyte growth factor were higher in fatal than nonfatal LF cases. Platelet disaggregation occurred only in samples from fatal LF cases. The impaired homeostasis and platelet dysfunction implicate alterations in the protein C pathway, which might contribute to the loss of endothelial barrier function in fatal infections. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
35. Crimean-Congo hemorrhagic fever virus strains Hoti and Afghanistan cause viremia and mild clinical disease in cynomolgus monkeys.
- Author
-
Cross, Robert W., Prasad, Abhishek N., Borisevich, Viktoriya, Geisbert, Joan B., Agans, Krystle N., Deer, Daniel J., Fenton, Karla A., and Geisbert, Thomas W.
- Subjects
KRA ,HEMORRHAGIC fever ,VACCINE development ,MEDICAL screening ,TICK infestations ,VIREMIA - Abstract
Background: Development of vaccines and therapies against Crimean-Congo hemorrhagic fever virus (CCHFV) have been hindered by the lack of immunocompetent animal models. Recently, a lethal nonhuman primate model based on the CCHFV Hoti strain was reported. CCHFV Hoti caused severe disease in cynomolgus monkeys with 75% lethality when given by the intravenous (i.v.) route. Methodology/Principal findings: In a series of experiments, eleven cynomologus monkeys were exposed i.v. to CCHFV Hoti and four macaques were exposed i.v. to CCHFV Afghanistan. Despite transient viremia and changes in clinical pathology such as leukopenia and thrombocytopenia developing in all 15 animals, all macaques survived to the study endpoint without developing severe disease. Conclusions/Significance: We were unable to attribute differences in the results of our study versus the previous report to differences in the CCHFV Hoti stock, challenge dose, origin, or age of the macaques. The observed differences are most likely the result of the outbred nature of macaques and low animal numbers often used by necessity and for ethical considerations in BSL-4 studies. Nonetheless, while we were unable to achieve severe disease or lethality, the CCHFV Hoti and Afghanistan macaque models are useful for screening medical countermeasures using biomarkers including viremia and clinical pathology to assess efficacy. Author summary: Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus in the family Nairoviridae, and is the etiological agent of a severe and potentially fatal hemorrhagic fever disease in humans (CCHF). Despite being the most geographically widespread tick-borne arbovirus, CCHFV remains understudied, and the lack of specific pre- and post-exposure medical countermeasures for CCHFV infection has led to its inclusion in the World Health Organization (WHO) list of pathogens requiring urgent research attention. Development and approval of vaccines and therapeutics against CCHFV necessitates efficacy testing in animal models that accurately recapitulate human disease. Recently, a lethal model for CCHF in cynomolgus macaques utilizing the Hoti strain of CCHFV was reported. We sought to verify and expand on this model by inclusion of an additional CCHFV strain (Afghanistan), animals from different geographic origins, and assessing the impact of age. In contrast to the previous work, none of the animals in our study developed severe or lethal disease. Importantly, we were unable to attribute these contrasting findings with differences in experimental parameters, implying that the discrepancy between the findings in the previous study and ours is likely due to the outbred nature of the animals and the small number of animals used in BSL-4 studies. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
36. Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment.
- Author
-
Cross, Robert W., Bornholdt, Zachary A., Prasad, Abhishek N., Geisbert, Joan B., Borisevich, Viktoriya, Agans, Krystle N., Deer, Daniel J., Melody, Kevin, Fenton, Karla A., Feldmann, Heinz, Sprecher, Armand, Zeitlin, Larry, and Geisbert, Thomas W.
- Subjects
VACCINATION ,VESICULAR stomatitis ,RHESUS monkeys ,EBOLA virus ,IMMUNOGLOBULINS - Abstract
A replication-competent vesicular stomatitis virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully used during the 2013-16 EBOV epidemic. Additionally, chimeric and human monoclonal antibodies (mAb) against the EBOV GP have shown promise in animals and humans when administered therapeutically. Uncertainty exists regarding the efficacy of postexposure antibody treatments in the event of a known exposure of a recent rVSV-ZEBOV vaccinee. Here, we model a worst-case scenario using rhesus monkeys vaccinated or unvaccinated with the rVSV-ZEBOV vaccine. We demonstrate that animals challenged with a uniformly lethal dose of EBOV one day following vaccination, and then treated with the anti-EBOV GP mAb MIL77 starting 3 days postexposure show no evidence of clinical illness and survive challenge. In contrast, animals receiving only vaccination or only mAb-based therapy become ill, with decreased survival compared to animals vaccinated and subsequently treated with MIL77. These results suggest that rVSV-ZEBOV augments immunotherapy. During an ongoing Ebola virus outbreak, infection before onset of protective immunity from vaccination is a possible scenario. Here the authors show in non-human primates that vaccination shortly before treatment with a monoclonal antibody does not negatively affect effectiveness of the antibody therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
37. Resistance of Cynomolgus Monkeys to Nipah and Hendra Virus Disease Is Associated With Cell-Mediated and Humoral Immunity.
- Author
-
Prasad, Abhishek N, Woolsey, Courtney, Geisbert, Joan B, Agans, Krystle N, Borisevich, Viktoriya, Deer, Daniel J, Mire, Chad E, Cross, Robert W, Fenton, Karla A, Broder, Christopher C, and Geisbert, Thomas W
- Subjects
KRA ,NIPAH virus ,HUMORAL immunity ,VIRUS diseases ,CELLULAR immunity ,RNA virus infections ,VIRAL physiology ,RESEARCH ,ANIMAL diseases ,ANIMAL experimentation ,VIRAL load ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,PRIMATES ,ANTIBODY formation ,COMPARATIVE studies ,PARAMYXOVIRUSES - Abstract
Background: The henipaviruses, Hendra virus (HeV) and Nipah virus (NiV), are capable of causing severe and often lethal respiratory and/or neurologic disease in animals and humans. Given the sporadic nature of henipavirus outbreaks, licensure of vaccines and therapeutics for human use will likely require demonstration of efficacy in animal models that faithfully reproduce the human condition. Currently, the African green monkey (AGM) best mimics human henipavirus-induced disease.Methods: The pathogenic potential of HeV and both strains of NiV (Malaysia, Bangladesh) was assessed in cynomolgus monkeys and compared with henipavirus-infected historical control AGMs. Multiplex gene and protein expression assays were used to compare host responses.Results: In contrast to AGMs, in which henipaviruses cause severe and usually lethal disease, HeV and NiVs caused only mild or asymptomatic infections in macaques. All henipaviruses replicated in macaques with similar kinetics as in AGMs. Infection in macaques was associated with activation and predicted recruitment of cytotoxic CD8+ T cells, Th1 cells, IgM+ B cells, and plasma cells. Conversely, fatal outcome in AGMs was associated with aberrant innate immune signaling, complement dysregulation, Th2 skewing, and increased secretion of MCP-1.Conclusion: The restriction factors identified in macaques can be harnessed for development of effective countermeasures against henipavirus disease. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
38. A Cross-Reactive Humanized Monoclonal Antibody Targeting Fusion Glycoprotein Function Protects Ferrets Against Lethal Nipah Virus and Hendra Virus Infection.
- Author
-
Mire, Chad E, Chan, Yee-Peng, Borisevich, Viktoriya, Cross, Robert W, Yan, Lianying, Agans, Krystle N, Dang, Ha V, Veesler, David, Fenton, Karla A, Geisbert, Thomas W, and Broder, Christopher C
- Subjects
NIPAH virus ,VIRUS diseases ,MONOCLONAL antibodies ,FERRET ,ANIMAL diseases ,THERAPEUTIC use of monoclonal antibodies ,PROTEINS ,RNA virus infections ,ANTIGEN-antibody reactions ,RESEARCH ,ANIMAL experimentation ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,PARAMYXOVIRUSES ,MAMMALS - Abstract
Background: Nipah virus (NiV) and Hendra virus (HeV) are zoonotic paramyxoviruses that cause severe disease in both animals and humans. There are no approved vaccines or treatments for use in humans; however, therapeutic treatment of both NiV and HeV infection in ferrets and non-human primates with a cross-reactive, neutralizing human monoclonal antibody (mAb), m102.4, targeting the G glycoprotein has been demonstrated. In a previous study, we isolated, characterized, and humanized a cross-reactive, neutralizing anti-F mAb (h5B3.1). The mAb h5B3.1 blocks the required F conformational change needed to facilitate membrane fusion and virus infection, and the epitope recognized by h5B3.1 has been structurally defined; however, the efficacy of h5B3.1 in vivo is unknown.Methods: The post-infection antiviral activity of h5B3.1 was evaluated in vivo by administration in ferrets after NiV and HeV virus challenge.Results: All subjects that received h5B3.1 from 1 to several days after infection with a high-dose, oral-nasal virus challenge were protected from disease, whereas all controls died.Conclusions: This is the first successful post-exposure antibody therapy for NiV and HeV using a humanized cross-reactive mAb targeting the F glycoprotein, and the findings suggest that a combination therapy targeting both F and G should be evaluated as a therapy for NiV/HeV infection. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
39. A Lethal Aerosol Exposure Model of Nipah Virus Strain Bangladesh in African Green Monkeys.
- Author
-
Prasad, Abhishek N, Agans, Krystle N, Sivasubramani, Satheesh K, Geisbert, Joan B, Borisevich, Viktoriya, Mire, Chad E, Lawrence, William S, Fenton, Karla A, and Geisbert, Thomas W
- Subjects
CERCOPITHECUS aethiops ,NIPAH virus ,AEROSOLS ,BIOLOGICAL weapons ,PATHOLOGY - Abstract
The high case-fatality rates and potential for use as a biological weapon make Nipah virus (NiV) a significant public health concern. Previous studies assessing the pathogenic potential of NiV delivered by the aerosol route in African green monkeys (AGMs) used the Malaysia strain (NiVM), which has caused lower instances of respiratory illness and person-to-person transmission during human outbreaks than the Bangladesh strain (NiVB). Accordingly, we developed a small particle aerosol model of NiVB infection in AGMs. Consistent with other mucosal AGM models of NiVB infection, we achieved uniform lethality and disease pathogenesis reflective of that observed in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
40. An Intranasal Exposure Model of Lethal Nipah Virus Infection in African Green Monkeys.
- Author
-
Geisbert, Joan B, Borisevich, Viktoriya, Prasad, Abhishek N, Agans, Krystle N, Foster, Stephanie L, Deer, Daniel J, Cross, Robert W, Mire, Chad E, Geisbert, Thomas W, and Fenton, Karla A
- Subjects
CERCOPITHECUS aethiops ,NIPAH virus ,VIRUS diseases ,LARYNGEAL masks ,ANIMAL models in research - Abstract
Due to the difficulty in conducting clinical trials for vaccines and treatments against Nipah virus (NiV), licensure will likely require animal models, most importantly non-human primates (NHPs). The NHP models of infection have primarily relied on intratracheal instillation or small particle aerosolization of NiV. However, neither of these routes adequately models natural mucosal exposure to NiV. To develop a more natural NHP model, we challenged African green monkeys with the Bangladesh strain of NiV by the intranasal route using the laryngeal mask airway (LMA) mucosal atomization device (MAD). LMA MAD exposure resulted in uniformly lethal disease that accurately reflected the human condition. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
41. Rational design of universal immunotherapy for TfR1-tropic arenaviruses.
- Author
-
Cohen-Dvashi, Hadas, Amon, Ron, Agans, Krystle N., Cross, Robert W., Borenstein-Katz, Aliza, Mateo, Mathieu, Baize, Sylvain, Padler-Karavani, Vered, Geisbert, Thomas W., and Diskin, Ron
- Subjects
IMMUNOTHERAPY ,ARENAVIRUSES ,BIOLOGICAL weapons ,GLYCOPROTEINS ,TRANSFERRIN - Abstract
Certain arenaviruses that circulate in rodent populations can cause life-threatening hemorrhagic fevers when they infect humans. Due to their efficient transmission, arenaviruses pose a severe risk for outbreaks and might be exploited as biological weapons. Effective countermeasures against these viruses are highly desired. Ideally, a single remedy would be effective against many or even all the pathogenic viruses in this family. However, despite the fact that all pathogenic arenaviruses from South America utilize transferrin receptor 1 (TfR1) as a cellular receptor, their viral glycoproteins are highly diversified, impeding efforts to isolate cross-neutralizing antibodies. Here we address this problem using a rational design approach to target TfR1-tropic arenaviruses with high potency and breadth. The pan-reactive molecule is highly effective against all arenaviruses that were tested, offering a universal therapeutic approach. Our design scheme avoids the shortcomings of previous immunoadhesins and can be used to combat other zoonotic pathogens. New World arenaviruses utilize the cellular transferrin receptor 1 (TfR1) to enter host cells. Here, the authors develop a TfR1-mimetic immunoadhesin, Arenacept, that targets viral spike complexes and exerts effective pan-reactive neutralization against pathogenic mammarenaviruses. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
42. Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease.
- Author
-
Mire, Chad E., Geisbert, Joan B., Agans, Krystle N., Versteeg, Krista M., Deer, Daniel J., Satterfield, Benjamin A., Fenton, Karla A., and Geisbert, Thomas W.
- Subjects
VIRAL vaccines ,VESICULAR stomatitis ,VIRUS diseases ,NIPAH virus ,CERCOPITHECUS aethiops ,RESEARCH funding - Abstract
Nipah virus (NiV) is a zoonotic pathogen that causes high case-fatality rates (CFRs) in humans. Two NiV strains have caused outbreaks: the Malaysia strain (NiVM), discovered in 1998-1999 in Malaysia and Singapore (≈40% CFR); and the Bangladesh strain (NiVB), discovered in Bangladesh and India in 2001 (≈80% CFR). Recently, NiVB in African green monkeys resulted in a more severe and lethal disease than NiVM. No NiV vaccines or treatments are licensed for human use. We assessed replication-restricted single-injection recombinant vesicular stomatitis vaccine NiV vaccine vectors expressing the NiV glycoproteins against NiVB challenge in African green monkeys. All vaccinated animals survived to the study endpoint without signs of NiV disease; all showed development of NiV F Ig, NiV G IgG, or both, as well as neutralizing antibody titers. These data show protective efficacy against a stringent and relevant NiVB model of human infection. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
43. Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms.
- Author
-
Warfield, Kelly L, Howell, Katie A, Vu, Hong, Geisbert, Joan, Wong, Gary, Shulenin, Sergey, Sproule, Stephanie, Holtsberg, Frederick W, Leung, Daisy W, Amarasinghe, Gaya K, Swenson, Dana L, Bavari, Sina, Kobinger, Gary P, Geisbert, Thomas W, and Aman, M Javad
- Subjects
EBOLA virus disease prevention ,IMMUNOGLOBULIN G ,VIRION ,EBOLA virus disease vaccines ,GLYCOPROTEINS ,ANIMAL experimentation ,COMPARATIVE studies ,EBOLA virus disease ,HYDROGEN-ion concentration ,IMMUNIZATION ,RESEARCH methodology ,MEDICAL cooperation ,PRIMATES ,PROTEINS ,RESEARCH ,VIRAL antibodies ,VIRAL vaccines ,VIRUSES ,EVALUATION research - Abstract
Background: Several vaccine platforms have been successfully evaluated for prevention of Ebola virus (EBOV) disease (EVD) in nonhuman primates and humans. Despite remarkable efficacy by multiple vaccines, the immunological correlates of protection against EVD are incompletely understood.Methods: We systematically evaluated the antibody response to various EBOV proteins in 79 nonhuman primates vaccinated with various EBOV vaccine platforms. We evaluated the serum immunoglobulin (Ig)G titers against EBOV glycoprotein (GP), the ability of the vaccine-induced antibodies to bind GP at acidic pH or to displace ZMapp, and virus neutralization titers. The correlation of these outcomes with survival from EVD was evaluated by appropriate statistical methods.Results: Irrespective of the vaccine platform, protection from EVD strongly correlated with anti-GP IgG titers. The GP-directed antibody levels required for protection in animals vaccinated with virus-like particles (VLPs) lacking nucleoprotein (NP) was significantly higher than animals immunized with NP-containing VLPs or adenovirus-expressed GP, platforms that induce strong T-cell responses. Furthermore, protective immune responses correlated with anti-GP antibody binding strength at acidic pH, neutralization of GP-expressing pseudovirions, and the ability to displace ZMapp components from GP.Conclusions: These findings suggest key quantitative and qualitative attributes of antibody response to EVD vaccines as potential correlates of protection. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
44. Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates.
- Author
-
Woolsey, Courtney, Geisbert, Joan B, Matassov, Demetrius, Agans, Krystle N, Borisevich, Viktoriya, Cross, Robert W, Deer, Daniel J, Fenton, Karla A, Eldridge, John H, Mire, Chad E, and Geisbert, Thomas W
- Subjects
VESICULAR stomatitis ,MARBURG virus ,GLYCOPROTEINS ,DISEASE progression ,FILOVIRIDAE - Abstract
A recombinant vesicular stomatitis virus (rVSV) expressing the Marburg virus (MARV) Musoke variant glycoprotein fully protects macaques against 2 MARV variants and Ravn virus as a preventive vaccine and MARV variant Musoke as a postexposure treatment. To evaluate postexposure efficacy against the most pathogenic MARV variant, Angola, we engineered rVSVs expressing homologous Angola glycoprotein. Macaques were challenged with high or low doses of variant Angola and treated 20-30 minutes after exposure. A total of 25% and 60%-75% of treated macaques survived the high-dose and low-dose challenges, respectively. The more rapid disease progression of variant Angola versus variant Musoke may account for the incomplete protection observed. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
45. Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret (Mustela putorius furo).
- Author
-
Cross, Robert W, Mire, Chad E, Agans, Krystle N, Borisevich, Viktoriya, Fenton, Karla A, and Geisbert, Thomas W
- Subjects
EBOLA virus ,MARBURG virus ,IMMUNITY ,FILOVIRIDAE ,FERRET ,ANIMAL experimentation ,BIOLOGICAL models ,COMPARATIVE studies ,MAMMALS ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,RNA viruses ,VIRAL antibodies ,EVALUATION research ,RNA virus infections - Abstract
The domestic ferret was recently described as a uniformly lethal model for 3 species of Ebolavirus. More importantly, this new model utilizes nonadapted wild-type Ebolaviruses. Here, in a proof-of-concept study, we infected ferrets with different variants of the closely related Marburg and Ravn viruses using different doses and routes of exposure. Although ferrets produced a neutralizing humoral response to challenge, we did not observe disease or viremia in any animal. The lack of disease in ferrets underscores the notion that differential mechanisms to immunity among filoviruses exist and may provide a model to better understand how differences contribute to disease. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
46. Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates.
- Author
-
Gilchuk, Pavlo, Mire, Chad E, Geisbert, Joan B, Agans, Krystle N, Deer, Daniel J, Cross, Robert W, Slaughter, James C, Flyak, Andrew I, Mani, Jeremy, Pauly, Michael H, Velasco, Jesus, Whaley, Kevin J, Zeitlin, Larry, Geisbert, Thomas W, and Crowe, James E Jr
- Subjects
TREATMENT of Ebola virus diseases ,EPIDEMICS ,MONOCLONAL antibodies ,DRUG efficacy ,PREVENTIVE medicine ,THERAPEUTIC use of immunoglobulins ,THERAPEUTIC use of monoclonal antibodies ,ANIMAL experimentation ,COMPARATIVE studies ,EBOLA virus disease ,RESEARCH methodology ,MEDICAL cooperation ,PRIMATES ,RESEARCH ,VIRAL antibodies ,EVALUATION research - Abstract
Background: The 2013-2016 Ebola virus disease (EVD) epidemics in West Africa highlighted a need for effective therapeutics for treatment of the disease caused by filoviruses. Monoclonal antibodies (mAbs) are promising therapeutic candidates for prophylaxis or treatment of virus infections. Data about efficacy of human mAb monotherapy against filovirus infections in preclinical nonhuman primate models are limited.Methods: Previously, we described a large panel of human mAbs derived from the circulating memory B cells from Bundibugyo virus (BDBV) infection survivors that bind to the surface glycoprotein (GP) of the virus. We tested one of these neutralizing mAbs that recognized the glycan cap of the GP, designated mAb BDBV289, as monotherapy in rhesus macaques.Results: We found that recombinant mAb BDBV289-N could confer up to 100% protection to BDBV-infected rhesus macaques when treatment was initiated as late as 8 days after virus challenge. Protection was associated with survival and decreased viremia levels in the blood of treated animals.Conclusions: These findings define the efficacy of monotherapy of lethal BDBV infection with a glycan cap-specific mAb and identify a candidate mAb therapeutic molecule that could be included in antibody cocktails for prevention or treatment of ebolavirus infections. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
47. Comparative Transcriptomics in Ebola Makona-Infected Ferrets, Nonhuman Primates, and Humans.
- Author
-
Cross, Robert W, Speranza, Emily, Borisevich, Viktoriya, Widen, Steven G, Wood, Thomas G, Shim, Rebecca S, Adams, Ricky D, Gerhardt, Dawn M, Bennett, Richard S, Honko, Anna N, Johnson, Joshua C, Hensley, Lisa E, Geisbert, Thomas W, and Connor, John H
- Subjects
TRANSCRIPTOMES ,EBOLA virus ,FERRET ,EBOLA virus disease ,GENOMES - Abstract
The domestic ferret is a uniformly lethal model of infection for 3 species of Ebolavirus known to be pathogenic in humans. Reagents to systematically analyze the ferret host response to infection are lacking; however, the recent publication of a draft ferret genome has opened the potential for transcriptional analysis of ferret models of disease. In this work, we present comparative analysis of longitudinally sampled blood taken from ferrets and nonhuman primates infected with lethal doses of the Makona variant of Zaire ebolavirus. Strong induction of proinflammatory and prothrombotic signaling programs were present in both ferrets and nonhuman primates, and both transcriptomes were similar to previously published datasets of fatal cases of human Ebola virus infection. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
48. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.
- Author
-
Callendret, Benoit, Vellinga, Jort, Wunderlich, Kerstin, Rodriguez, Ariane, Steigerwald, Robin, Dirmeier, Ulrike, Cheminay, Cedric, Volkmann, Ariane, Brasel, Trevor, Carrion, Ricardo, Giavedoni, Luis D., Patterson, Jean L., Mire, Chad E., Geisbert, Thomas W., Hooper, Jay W., Weijtens, Mo, Hartkoorn-Pasma, Jutta, Custers, Jerome, Grazia Pau, Maria, and Schuitemaker, Hanneke
- Subjects
VIRAL vaccines ,FILOVIRIDAE ,EBOLA virus disease ,MULTIVALENT molecules ,GLYCOPROTEINS - Abstract
The search for a universal filovirus vaccine that provides protection against multiple filovirus species has been prompted by sporadic but highly lethal outbreaks of Ebolavirus and Marburgvirus infections. A good prophylactic vaccine should be able to provide protection to all known filovirus species and as an upside potentially protect from newly emerging virus strains. We investigated the immunogenicity and protection elicited by multivalent vaccines expressing glycoproteins (GP) from Ebola virus (EBOV), Sudan virus (SUDV), Taï Forest virus (TAFV) and Marburg virus (MARV). Immune responses against filovirus GP have been associated with protection from disease. The GP antigens were expressed by adenovirus serotypes 26 and 35 (Ad26 and Ad35) and modified Vaccinia virus Ankara (MVA) vectors, all selected for their strong immunogenicity and good safety profile. Using fully lethal NHP intramuscular challenge models, we assessed different vaccination regimens for immunogenicity and protection from filovirus disease. Heterologous multivalent Ad26-Ad35 prime-boost vaccination regimens could give full protection against MARV (range 75%-100% protection) and EBOV (range 50% to 100%) challenge, and partial protection (75%) against SUDV challenge. Heterologous multivalent Ad26-MVA prime-boost immunization gave full protection against EBOV challenge in a small cohort study. The use of such multivalent vaccines did not show overt immune interference in comparison with monovalent vaccines. Multivalent vaccines induced GP-specific antibody responses and cellular IFNγ responses to each GP expressed by the vaccine, and cross-reactivity to TAFV GP was detected in a trivalent vaccine expressing GP from EBOV, SUDV and MARV. In the EBOV challenge studies, higher humoral EBOV GP-specific immune responses (p = 0.0004) were associated with survival from EBOV challenge and less so for cellular immune responses (p = 0.0320). These results demonstrate that it is feasible to generate a multivalent filovirus vaccine that can protect against lethal infection by multiple members of the filovirus family. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
49. Single-Vector, Single-Injection Recombinant Vesicular Stomatitis Virus Vaccines Against High-Containment Viruses.
- Author
-
Whitt, Michael A., Geisbert, Thomas W., and Mire, Chad E.
- Published
- 2016
- Full Text
- View/download PDF
50. Transcriptome Analysis of Circulating Immune Cell Subsets Highlight the Role of Monocytes in Zaire Ebola Virus Makona Pathogenesis.
- Author
-
Menicucci, Andrea R., Versteeg, Krista, Woolsey, Courtney, Mire, Chad E., Geisbert, Joan B., Cross, Robert W., Agans, Krystle N., Jankeel, Allen, Geisbert, Thomas W., and Messaoudi, Ilhem
- Subjects
EBOLA virus disease ,IMMUNITY ,MACROPHAGES - Abstract
Existing models of Ebola virus disease (EVD) suggest antigen-presenting cells are initial targets of Zaire ebolavirus (ZEBOV). In vitro studies have shown that ZEBOV infection of monocytes and macrophages results in the production of inflammatory mediators, which may cause lymphocyte apoptosis. However, these findings have not been corroborated by in vivo studies. In this study, we report the first longitudinal analysis of transcriptional changes in purified monocytes, T-cells, and B-cells isolated from cynomolgus macaques following infection with ZEBOV-Makona. Our data reveal monocytes as one of the major immune cell subsets that supports ZEBOV replication in vivo. In addition, we report a marked increase in the transcription of genes involved in inflammation, coagulation, and vascular disease within monocytes, suggesting that monocytes contribute to EVD manifestations. Further, genes important for antigen presentation and regulation of immunity were downregulated, potentially subverting development of adaptive immunity. In contrast, lymphocytes, which do not support ZEBOV replication, showed transcriptional changes limited to a small number of interferon-stimulated genes (ISGs) and a failure to upregulate genes associated with an antiviral effector immune response. Collectively, these data suggest that ZEBOV-infected monocytes play a significant role in ZEBOV-Makona pathogenesis and strategies to suppress virus replication or modify innate responses to infection in these cells should be a priority for therapeutic intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.